List view / Grid view
Episode 5 – Small molecule screening with Dr Sheraz Gul, Fraunhofer Institute & Dr John Fuller, Beckman Coulter
In this latest episode, we discuss how small molecule discovery can be automated and how this process saves researchers time and money.
Altasciences has announced its acquisition of Sinclair Research, a pre-clinical CRO, to expand its services across the US.
16 December 2021 | By Eurofins DiscoverX and Sanford Burnham Prebys Medical Discovery Institute
Join this live webinar to learn about orphan GPCRs as drug targets and the challenges related to lead identification.
Researchers have found a quinoxaline-core containing, non-genotoxic lead compound that could treat schistosomiasis following optimisation.
A new 6-chromanol-derived compound named SUL-138 has shown promise in animal models at treating acute kidney injury.
Scientists unveil the role of KCNQ2/3 using a functional screen of 40 native US plants and identify nine extracts that could treat diarrhoea.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
This whitepaper overviews use of Advanced Flow Cytometry to accelerate antibody screening and characterisation and reveal deeper biological insights.
19 August 2021 | By 10X Genomics
Explore the latest developments in screening technologies and how drug discovery has changed during the past decades in our webinar with 10X Genomics.
Cardiac proarrhythmic risk assessment using human-induced pluripotent stem cell-derived cardiomyocytes
19 August 2021 | By Eurofins Discovery
Watch this on-demand webinar that discusses the two assays developed by Eurofins and why they represent a more physiologic and dynamic system to provide a more comprehensive pre-clinical model for cardiac liability assessment.